Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as 0.3% BOL-303242-X ophthalmic suspension
0.3% BOL-303242-X · 1 trial · 1 indication
Total corneal staining score was calculated by adding the individual grades from 5 regions of the corneal surface (1: Central; 2: Superior; 3: Temporal; 4: Nasal; 5: Inferior). Grade 0 = none and Grade 3 = severe. The minimum total score possible was 0 and the maximum total score possible was 15. Higher scores indicated worse outcome.
Each symptom (ocular discomfort, dryness, grittiness, and stinging) was assessed to the nearest millimeter on a 0 - 10 cm Visual Analog Scale (VAS) by the subject. The worst VAS dry eye symptom was utilized in the analysis. The minimum for the worst symptom was 0 and the maximum for the worst symptom was 10.
| Arm | Type | Description |
|---|---|---|
| 0.3% BOL-303242-X ophthalmic suspension | EXPERIMENTAL | 0.3% BOL-303242-X ophthalmic suspension |
| 2% BOL-303242-X ophthalmic suspension | EXPERIMENTAL | 2% BOL-303242-X ophthalmic suspension |
| Vehicle | PLACEBO_COMPARATOR | Vehicle twice daily (BID) |
| 1% BOL-303242-X ophthalmic suspension | EXPERIMENTAL | 1% BOL-303242-X ophthalmic suspension |
| 2% BOL-303242-X ophthalmic suspension in the morning | EXPERIMENTAL | 2% BOL-303242-X ophthalmic suspension in the morning (AM) and vehicle in the afternoon (PM) |
| 2% BOL-303242-X ophthalmic suspension PM | EXPERIMENTAL | Vehicle in the AM and 2% BOL-303242-X ophthalmic suspension in the PM. |
| Name | Type | Description |
|---|---|---|
| 0.3% BOL-303242-X ophthalmic suspension | DRUG | 0.3% BOL-303242-X ophthalmic suspension BID for 12 weeks. |
| 2% BOL-303242-X ophthalmic suspension | DRUG | 2% BOL-303242-X ophthalmic suspension BID for 12 weeks. |
| Placebo Comparator: Vehicle | DRUG | Placebo Comparator: Vehicle BID for 12 weeks. |
| 1% BOL-303242-X ophthalmic suspension | DRUG | 1% BOL-303242-X ophthalmic suspension BID for 12 weeks. |
| 2% BOL-303242-X ophthalmic suspension AM | DRUG | 2% BOL-303242-X ophthalmic suspension once daily (QD) AM and vehicle QD in PM for 12 weeks. |
| 2% BOL-303242-X ophthalmic suspension PM | DRUG | Vehicle QD AM and 2% BOL-303242-X ophthalmic suspension QD in PM for 12 weeks. |
Inclusion Criteria: * Subjects who have a diagnosis of dry eye disease. * Intraocular pressure (IOP) ≤28 mmHg with no IOP lowering medications. * Subjects who are willing and able to refrain from using contact lenses during the study. Exclusion Criteria: * Subjects with known hypersensitivity or ...
Top 2 of 7 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Akebia Therapeutics, Inc. | AKBA | 1 | PHASE2 | Vadadustat |
| Rigel Pharmaceuticals, Inc. | RIGL | 1 | PHASE2 | Fostamatinib |
0.3% BOL-303242-X is an investigational small molecule ophthalmic suspension being developed by Bausch + Lomb Corporation for Dry Eye Syndrome. It is a sterile topical eye drop formulation. The asset has completed a single Phase 2 clinical trial and is not approved for commercial use.
0.3% BOL-303242-X is being studied for the treatment of Dry Eye Syndrome, an ophthalmology condition. Its only recorded clinical trial enrolled adults 18 years and older with Dry Eye Syndrome in the United States. The drug remains investigational and has not been cleared for any approved use.
Bausch + Lomb Corporation develops 0.3% BOL-303242-X. The company trades on the New York Stock Exchange under the ticker BLCO. Bausch + Lomb is an eye health company, and this ophthalmic suspension sits within its ophthalmology pipeline as an investigational Phase 2 asset.
0.3% BOL-303242-X is in Phase 2 development. One Phase 2 trial has been completed, and no active trials are currently listed. Because the program has not advanced beyond Phase 2, the drug is investigational and has not received FDA approval for Dry Eye Syndrome.
0.3% BOL-303242-X has been evaluated in one completed Phase 2 study, NCT01163643, titled Study to Assess the Safety and Efficacy of BOL-303242-X Ophthalmic Suspension in Dry Eye Syndrome. The trial was randomized, double blind, and placebo controlled, enrolling 356 participants in the United States.
Yes. 0.3% BOL-303242-X ophthalmic suspension is the same asset as 0.3% BOL-303242-X. The longer name describes the topical eye drop dosage form used in the Phase 2 Dry Eye Syndrome trial, while the shorter name is the drug identifier used in pipeline references.